Gilead chief Daniel O’Day isn’t done making headlines — with more R&D deals and lots of new hires to come
Gilead CEO Daniel O’Day isn’t about to stop doing R&D deals now that he’s completed a record-setting $5 billion collaboration with Galapagos — even if he does have some top executive positions to fill.
In their Q2 call with analysts Tuesday, O’Day highlighted a few key notions.
Basic subscription required
Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.